Taro Pharmaceuticals is voluntarily recalling 44,256 bottles of Nortriptyline HCl (nortriptyline hydrochloride) Capsules, 10mg, due to deviations from Current Good Manufacturing Practice (CGMP) standards. This prescription antidepressant was distributed in bottles of 100 capsules across the United States. While no specific patient injuries have been reported, consumers should contact their healthcare provider or pharmacist if they have used this medication and have concerns.
The recall is due to manufacturing process deviations (CGMP deviations), which means the product may not meet the quality and purity standards required by the FDA. Using a drug that does not meet these standards could lead to variations in the medication's effectiveness or safety.
Healthcare consultation and pharmacy refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.